The Filings Report

Twist Bioscience Corporation Common Stock

TWSTNasdaqCIK 1581280Healthcare / Biotechnologyfiscal year ends September35 quarters since 2017

Revenue, Q3 FY2026
$118M
+23.2% on Q3 FY2025
Net income
−$35M
−271.9% on Q3 FY2025
Free cash flow
−$9M
+18.1% on Q3 FY2025
Diluted EPS
$-0.56
−269.7% on Q3 FY2025
Revenue, TTM
$432M
trailing four quarters
Net margin, TTM
-31.7%
net income −$137M
Free cash flow, TTM
−$93M
−$53M less $40M capex
Cash and equivalents
$117M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+3.9%
63M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$7.6B
at the close, buybacks

Latest quarter Q3 FY2026, filed August 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended June 30, 2026, Twist Bioscience Corporation Common Stock reported revenue of $118M, +23.2% on Q3 FY2025, and net loss of $35M (−271.9%). Operating margin was −30.6%. Free cash flow, operating cash flow less capital expenditures, was −$9M ($1M less $10M). Diluted earnings per share were $-0.56.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

TWST daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $123.83 · H $130.90 · L $116.50 · C $120.79 · +0.15% on the dayOver the range: +294.35%, Nov 7, 2025 to Nov 6, 2026
$12$67$122$176$231Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of August 3, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200MQ4'22, Revenue: $57MQ4'22, Net income: −$51MQ4'22Q1'23, Revenue: $54MQ1'23, Net income: −$42MQ1'23Q2'23, Revenue: $60MQ2'23, Net income: −$59MQ2'23Q3'23, Revenue: $64MQ3'23, Net income: −$57MQ3'23Q4'23, Revenue: $67MQ4'23, Net income: −$46MQ4'23Q1'24, Revenue: $71MQ1'24, Net income: −$43MQ1'24Q2'24, Revenue: $75MQ2'24, Net income: −$45MQ2'24Q3'24, Revenue: $81MQ3'24, Net income: −$86MQ3'24Q4'24, Revenue: $85MQ4'24, Net income: −$35MQ4'24Q1'25, Revenue: $89MQ1'25, Net income: −$32MQ1'25Q2'25, Revenue: $93MQ2'25, Net income: −$39MQ2'25Q3'25, Revenue: $96MQ3'25, Net income: $20MQ3'25Q4'25, Revenue: $99MQ4'25, Net income: −$27MQ4'25Q1'26, Revenue: $104MQ1'26, Net income: −$31MQ1'26Q2'26, Revenue: $111MQ2'26, Net income: −$44MQ2'26Q3'26, Revenue: $118MQ3'26, Net income: −$35MQ3'26−$100M$0$100M$200MQ4'22, Revenue: $57MQ4'22, Net income: −$51MQ4'22Q1'23, Revenue: $54MQ1'23, Net income: −$42MQ1'23Q2'23, Revenue: $60MQ2'23, Net income: −$59MQ2'23Q3'23, Revenue: $64MQ3'23, Net income: −$57MQ3'23Q4'23, Revenue: $67MQ4'23, Net income: −$46MQ4'23Q1'24, Revenue: $71MQ1'24, Net income: −$43MQ1'24Q2'24, Revenue: $75MQ2'24, Net income: −$45MQ2'24Q3'24, Revenue: $81MQ3'24, Net income: −$86MQ3'24Q4'24, Revenue: $85MQ4'24, Net income: −$35MQ4'24Q1'25, Revenue: $89MQ1'25, Net income: −$32MQ1'25Q2'25, Revenue: $93MQ2'25, Net income: −$39MQ2'25Q3'25, Revenue: $96MQ3'25, Net income: $20MQ3'25Q4'25, Revenue: $99MQ4'25, Net income: −$27MQ4'25Q1'26, Revenue: $104MQ1'26, Net income: −$31MQ1'26Q2'26, Revenue: $111MQ2'26, Net income: −$44MQ2'26Q3'26, Revenue: $118MQ3'26, Net income: −$35MQ3'26−$100M$0$100M$200MQ4'22, Revenue: $57MQ4'22, Net income: −$51MQ1'23, Revenue: $54MQ1'23, Net income: −$42MQ1'23Q2'23, Revenue: $60MQ2'23, Net income: −$59MQ3'23, Revenue: $64MQ3'23, Net income: −$57MQ3'23Q4'23, Revenue: $67MQ4'23, Net income: −$46MQ1'24, Revenue: $71MQ1'24, Net income: −$43MQ1'24Q2'24, Revenue: $75MQ2'24, Net income: −$45MQ3'24, Revenue: $81MQ3'24, Net income: −$86MQ3'24Q4'24, Revenue: $85MQ4'24, Net income: −$35MQ1'25, Revenue: $89MQ1'25, Net income: −$32MQ1'25Q2'25, Revenue: $93MQ2'25, Net income: −$39MQ3'25, Revenue: $96MQ3'25, Net income: $20MQ3'25Q4'25, Revenue: $99MQ4'25, Net income: −$27MQ1'26, Revenue: $104MQ1'26, Net income: −$31MQ1'26Q2'26, Revenue: $111MQ2'26, Net income: −$44MQ3'26, Revenue: $118MQ3'26, Net income: −$35MQ3'26

Net income losses drawn in red.

Free cash flow
−$80M−$60M−$40M−$20M$0$20MQ4'22, Free cash flow: −$18MQ4'22Q1'23, Free cash flow: −$66MQ1'23Q2'23, Free cash flow: −$53MQ2'23Q3'23, Free cash flow: −$28MQ3'23Q4'23, Free cash flow: −$23MQ4'23Q1'24, Free cash flow: −$24MQ1'24Q2'24, Free cash flow: −$20MQ2'24Q3'24, Free cash flow: −$7MQ3'24Q4'24, Free cash flow: −$17MQ4'24Q1'25, Free cash flow: −$24MQ1'25Q2'25, Free cash flow: −$17MQ2'25Q3'25, Free cash flow: −$11MQ3'25Q4'25, Free cash flow: −$24MQ4'25Q1'26, Free cash flow: −$35MQ1'26Q2'26, Free cash flow: −$25MQ2'26Q3'26, Free cash flow: −$9MQ3'26−$80M−$60M−$40M−$20M$0$20MQ4'22, Free cash flow: −$18MQ4'22Q1'23, Free cash flow: −$66MQ1'23Q2'23, Free cash flow: −$53MQ2'23Q3'23, Free cash flow: −$28MQ3'23Q4'23, Free cash flow: −$23MQ4'23Q1'24, Free cash flow: −$24MQ1'24Q2'24, Free cash flow: −$20MQ2'24Q3'24, Free cash flow: −$7MQ3'24Q4'24, Free cash flow: −$17MQ4'24Q1'25, Free cash flow: −$24MQ1'25Q2'25, Free cash flow: −$17MQ2'25Q3'25, Free cash flow: −$11MQ3'25Q4'25, Free cash flow: −$24MQ4'25Q1'26, Free cash flow: −$35MQ1'26Q2'26, Free cash flow: −$25MQ2'26Q3'26, Free cash flow: −$9MQ3'26−$80M−$60M−$40M−$20M$0$20MQ4'22, Free cash flow: −$18MQ1'23, Free cash flow: −$66MQ1'23Q2'23, Free cash flow: −$53MQ3'23, Free cash flow: −$28MQ3'23Q4'23, Free cash flow: −$23MQ1'24, Free cash flow: −$24MQ1'24Q2'24, Free cash flow: −$20MQ3'24, Free cash flow: −$7MQ3'24Q4'24, Free cash flow: −$17MQ1'25, Free cash flow: −$24MQ1'25Q2'25, Free cash flow: −$17MQ3'25, Free cash flow: −$11MQ3'25Q4'25, Free cash flow: −$24MQ1'26, Free cash flow: −$35MQ1'26Q2'26, Free cash flow: −$25MQ3'26, Free cash flow: −$9MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $379MQ4'22Q1'23, Cash and equivalents: $317MQ1'23Q2'23, Cash and equivalents: $315MQ2'23Q3'23, Cash and equivalents: $307MQ3'23Q4'23, Cash and equivalents: $286MQ4'23Q1'24, Cash and equivalents: $266MQ1'24Q2'24, Cash and equivalents: $243MQ2'24Q3'24, Cash and equivalents: $239MQ3'24Q4'24, Cash and equivalents: $226MQ4'24Q1'25, Cash and equivalents: $221MQ1'25Q2'25, Cash and equivalents: $210MQ2'25Q3'25, Cash and equivalents: $201MQ3'25Q4'25, Cash and equivalents: $183MQ4'25Q1'26, Cash and equivalents: $149MQ1'26Q2'26, Cash and equivalents: $123MQ2'26Q3'26, Cash and equivalents: $117MQ3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $379MQ4'22Q1'23, Cash and equivalents: $317MQ1'23Q2'23, Cash and equivalents: $315MQ2'23Q3'23, Cash and equivalents: $307MQ3'23Q4'23, Cash and equivalents: $286MQ4'23Q1'24, Cash and equivalents: $266MQ1'24Q2'24, Cash and equivalents: $243MQ2'24Q3'24, Cash and equivalents: $239MQ3'24Q4'24, Cash and equivalents: $226MQ4'24Q1'25, Cash and equivalents: $221MQ1'25Q2'25, Cash and equivalents: $210MQ2'25Q3'25, Cash and equivalents: $201MQ3'25Q4'25, Cash and equivalents: $183MQ4'25Q1'26, Cash and equivalents: $149MQ1'26Q2'26, Cash and equivalents: $123MQ2'26Q3'26, Cash and equivalents: $117MQ3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $379MQ1'23, Cash and equivalents: $317MQ1'23Q2'23, Cash and equivalents: $315MQ3'23, Cash and equivalents: $307MQ3'23Q4'23, Cash and equivalents: $286MQ1'24, Cash and equivalents: $266MQ1'24Q2'24, Cash and equivalents: $243MQ3'24, Cash and equivalents: $239MQ3'24Q4'24, Cash and equivalents: $226MQ1'25, Cash and equivalents: $221MQ1'25Q2'25, Cash and equivalents: $210MQ3'25, Cash and equivalents: $201MQ3'25Q4'25, Cash and equivalents: $183MQ1'26, Cash and equivalents: $149MQ1'26Q2'26, Cash and equivalents: $123MQ3'26, Cash and equivalents: $117MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed August 3, 2026.

Twist Bioscience Corporation Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Jun 30, 2026filed Aug 3, 2026Q2 FY2026ended Mar 31, 2026filed May 4, 2026Q1 FY2026ended Dec 31, 2025filed Feb 2, 2026Q4 FY2025ended Sep 30, 2025filed Nov 17, 2025Q3 FY2025ended Jun 30, 2025filed Aug 4, 2025Q2 FY2025ended Mar 31, 2025filed May 5, 2025Q1 FY2025ended Dec 31, 2024filed Feb 3, 2025Q4 FY2024ended Sep 30, 2024filed Nov 18, 2024YoYQ3 FY2026vs Q3 FY2025
Revenue1181111049996938985+23.2%
Cost of revenue5654504845474646+24.9%
Gross profit—————————
Research and development1820171718242121−0.1%
Selling, general and administrative8176706463645653+27.4%
Operating income(36)(46)(33)(30)(30)(42)(35)(36)−20.5%
Other income (expense)0000(1)00(2)+104.8%
Pretax income(35)(44)(30)(27)21(39)(31)(35)−268.8%
Income tax00000000+62.8%
Net income(35)(44)(31)(27)20(39)(32)(35)−271.9%
Diluted EPS ($)(0.56)(0.71)(0.50)—0.33(0.66)(0.53)—−269.7%
Diluted shares (millions)626261—616059——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed August 3, 2026.

Twist Bioscience Corporation Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Jun 30, 2026filed Aug 3, 2026Q2 FY2026ended Mar 31, 2026filed May 4, 2026Q1 FY2026ended Dec 31, 2025filed Feb 2, 2026Q4 FY2025ended Sep 30, 2025filed Nov 17, 2025Q3 FY2025ended Jun 30, 2025filed Aug 4, 2025Q2 FY2025ended Mar 31, 2025filed May 5, 2025Q1 FY2025ended Dec 31, 2024filed Feb 3, 2025Q4 FY2024ended Sep 30, 2024filed Nov 18, 2024YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents117123149183201210221226−41.7%
Short-term investments4949494949474950−0.0%
Total current assets321323304333340338345347−5.4%
Total assets672676638642644596609614+4.5%
Total current liabilities120120809187757071+38.1%
Long-term debt—————————
Total liabilities227221182169165156153142+37.1%
Stockholders’ equity446455456473478440456473−6.8%
Shares outstanding (millions)6362616160606059—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed August 3, 2026.

Twist Bioscience Corporation Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Jun 30, 2026filed Aug 3, 2026Q2 FY2026ended Mar 31, 2026filed May 4, 2026Q1 FY2026ended Dec 31, 2025filed Feb 2, 2026Q4 FY2025ended Sep 30, 2025filed Nov 17, 2025Q3 FY2025ended Jun 30, 2025filed Aug 4, 2025Q2 FY2025ended Mar 31, 2025filed May 5, 2025Q1 FY2025ended Dec 31, 2024filed Feb 3, 2025Q4 FY2024ended Sep 30, 2024filed Nov 18, 2024YoYQ3 FY2026vs Q3 FY2025
Operating cash flow1(18)(25)(12)(1)(13)(21)(15)+179.6%
Capital expenditures10810129422+6.5%
Free cash flow (CFO − capex)(9)(25)(35)(24)(11)(17)(24)(17)+18.1%
Depreciation and amortization76666667+11.8%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed November 17, 2025.

Income statement

Twist Bioscience Corporation Common Stock income statement, annual
Millions of dollarsFY2025ended Sep 30, 2025filed Nov 17, 2025FY2024ended Sep 30, 2024filed Nov 18, 2024FY2023ended Sep 30, 2023filed Nov 21, 2023FY2022ended Sep 30, 2022filed Nov 28, 2022FY2021ended Sep 30, 2021filed Nov 23, 2021FY2020ended Sep 30, 2020filed Nov 27, 2020FY2019ended Sep 30, 2019filed Dec 13, 2019FY2018ended Sep 30, 2018filed Feb 11, 2019FY2017ended Sep 30, 2017filed Feb 11, 2019
Revenue37731324520413290542511
Cost of revenue1861801551198161473224
Gross profit—————————
Research and development80911071206943362019
Selling, general and administrative247218190213136103804326
Operating income(136)(221)(217)(235)(153)(140)(109)(71)(58)
Other income (expense)(1)(3)(1)(1)(1)0000
Pretax income(77)(208)(203)(228)(154)(140)(107)(71)(59)
Income tax111(10)(2)0000
Net income(78)(209)(205)(218)(152)(140)(108)(71)(59)
Diluted EPS ($)(1.30)(3.60)(3.60)(4.04)(3.15)(3.57)———
Diluted shares (millions)605857544839———

Balance sheet

Twist Bioscience Corporation Common Stock balance sheet, annual
Millions of dollarsFY2025ended Sep 30, 2025filed Nov 17, 2025FY2024ended Sep 30, 2024filed Nov 18, 2024FY2023ended Sep 30, 2023filed Nov 21, 2023FY2022ended Sep 30, 2022filed Nov 28, 2022FY2021ended Sep 30, 2021filed Nov 23, 2021FY2020ended Sep 30, 2020filed Nov 27, 2020FY2019ended Sep 30, 2019filed Dec 13, 2019FY2018ended Sep 30, 2018filed Feb 11, 2019FY2017ended Sep 30, 2017filed Feb 11, 2019
Cash and equivalents18322628637946694478131
Short-term investments4950501261219691——
Total current assets33334742459654633516096—
Total assets642614776961702399187116—
Total current liabilities9171739163363019—
Long-term debt—————147—
Total liabilities169142153172121633527—
Stockholders’ equity473473623789581336152(201)(133)
Shares outstanding (millions)61595857504533——

Cash flow statement

Twist Bioscience Corporation Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Sep 30, 2025filed Nov 17, 2025FY2024ended Sep 30, 2024filed Nov 18, 2024FY2023ended Sep 30, 2023filed Nov 21, 2023FY2022ended Sep 30, 2022filed Nov 28, 2022FY2021ended Sep 30, 2021filed Nov 23, 2021FY2020ended Sep 30, 2020filed Nov 27, 2020FY2019ended Sep 30, 2019filed Dec 13, 2019FY2018ended Sep 30, 2018filed Feb 11, 2019FY2017ended Sep 30, 2017filed Feb 11, 2019
Operating cash flow(48)(64)(142)(124)(112)(142)(88)(66)(51)
Capital expenditures2852810227101547
Free cash flow (CFO − capex)(76)(69)(170)(226)(139)(152)(103)(70)(58)
Depreciation and amortization25312917107665
Share repurchases—————————
Dividends paid—————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$117M
75 sales by 7 insiders; officers and directors $117M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$148M
180 sales by 10 insiders; officers and directors $148M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 3, 2026Cho DennisSee Remarksopen-market sale949$135.40$128K62,840Nov 5, 2026
Nov 3, 2026Finn Patrick JohnPresident and COOopen-market sale2,565$135.40$347K180,278Nov 5, 2026
Nov 3, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale4,573$135.40$619K558,187Nov 5, 2026
Nov 3, 2026Werner Robert F.Chief Accounting Officeropen-market sale148$135.40$20K42,769Nov 5, 2026
Nov 3, 2026Green PaulaSVP of Human Resourcesopen-market sale1,007$135.40$136K105,625Nov 5, 2026
Oct 23, 2026Finn Patrick JohnPresident and COOopen-market sale2,245$134.59$302K182,843Oct 27, 2026
Oct 9, 2026Laponis AdamChief Financial Officeropen-market sale2,462$156.30$385K98,114Oct 13, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-11,840$200.44$369K565,468Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1481$201.26$97K564,987Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-11,017$202.32$206K563,970Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1432$203.61$88K563,538Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1290$204.80$59K563,248Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1297$205.78$61K562,951Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1146$206.84$30K562,805Oct 7, 2026
Oct 5, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-145$207.46$9K562,760Oct 7, 2026
Oct 2, 2026Laponis AdamChief Financial Officeropen-market sale8,057$188.88$2M100,576Oct 5, 2026
Oct 2, 2026Green PaulaSVP of Human Resourcesopen-market sale10,088$188.88$2M106,632Oct 5, 2026
Oct 2, 2026Finn Patrick JohnPresident and COOopen-market sale25,714$188.88$5M185,088Oct 5, 2026
Oct 2, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-145,736$188.88$9M567,308Oct 5, 2026
Oct 2, 2026Cho DennisSee Remarksopen-market sale9,514$188.88$2M63,789Oct 5, 2026
Oct 2, 2026Werner Robert F.Chief Accounting Officeropen-market sale1,482$188.88$280K42,917Oct 5, 2026
Oct 1, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1655$200.00$131K613,044Oct 5, 2026
Sep 24, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-12,485$175.23$435K616,417Sep 25, 2026
Sep 24, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1945$176.39$167K615,472Sep 25, 2026
Sep 24, 2026Leproust Emily M.Chief Executive Officer, Directoropen-market sale10b5-1164$177.17$29K615,308Sep 25, 2026

Full insider history for Twist Bioscience Corporation Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 9; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Twist Bioscience Corporation, CIK 1581280 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2022
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerIncludingAssessedTax
Cost of revenue: CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/TWST.json